Zealand Financial Statements From 2010 to 2024
| ZEAL Stock | DKK 626.00 15.00 2.45% |
Check Zealand Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zealand main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Zealand financial statements analysis is a perfect complement when working with Zealand Pharma Valuation or Volatility modules.
Zealand |
Zealand Pharma AS Company Shares Owned By Insiders Analysis
Zealand Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Zealand Pharma Shares Owned By Insiders | 0.07 % |
Most of Zealand Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zealand Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 0.07% of Zealand Pharma AS are shares owned by insiders. This is 99.54% lower than that of the Healthcare sector and 99.51% lower than that of the Biotechnology industry. The shares owned by insiders for all Denmark stocks is 99.31% higher than that of the company.
Zealand Pharma AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zealand Pharma's current stock value. Our valuation model uses many indicators to compare Zealand Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zealand Pharma competition to find correlations between indicators driving Zealand Pharma's intrinsic value. More Info.Zealand Pharma AS is rated first in return on equity category among related companies. It is rated first in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Zealand Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Zealand Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zealand Pharma's earnings, one of the primary drivers of an investment's value.About Zealand Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Zealand Pharma income statement, its balance sheet, and the statement of cash flows. Zealand Pharma investors use historical funamental indicators, such as Zealand Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Zealand Pharma investors may use each financial statement separately, they are all related. The changes in Zealand Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zealand Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Zealand Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Zealand Pharma. Please read more on our technical analysis and fundamental analysis pages.
Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out the analysis of Zealand Pharma Correlation against competitors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Zealand Stock analysis
When running Zealand Pharma's price analysis, check to measure Zealand Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zealand Pharma is operating at the current time. Most of Zealand Pharma's value examination focuses on studying past and present price action to predict the probability of Zealand Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zealand Pharma's price. Additionally, you may evaluate how the addition of Zealand Pharma to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |